CTOs on the Move

iCo Therapeutics

www.icotherapeutics.com

 
iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Matthew Gibbs

CipherBio@SVB: Search life science fundraising news and data to discover innovative companies backed by venture investors https://t.co/mmTCuwa0Mc

Millennium Pharmaceuticals Inc

Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering

Arizant Healthcare

Arizant Healthcare is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurogene

Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families.

Victor International Mktg Inc

Victor International Mktg Inc is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.